200 related articles for article (PubMed ID: 10752477)
1. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
2. A3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells.
Tordsson J; Lavasani S; Ohlsson L; Karlström P; Svedberg H; Abrahmsén L; Brodin T
Int J Cancer; 2000 Aug; 87(4):559-68. PubMed ID: 10918198
[TBL] [Abstract][Full Text] [Related]
3. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library.
Desai SA; Wang X; Noronha EJ; Kageshita T; Ferrone S
Cancer Res; 1998 Jun; 58(11):2417-25. PubMed ID: 9622083
[TBL] [Abstract][Full Text] [Related]
5. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells.
Riemer AB; Hantusch B; Sponer B; Kraml G; Hafner C; Zielinski CC; Scheiner O; Pehamberger H; Jensen-Jarolim E
Cancer Immunol Immunother; 2005 Jul; 54(7):677-84. PubMed ID: 15565329
[TBL] [Abstract][Full Text] [Related]
6. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
8. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.
Forsberg G; Ohlsson L; Brodin T; Björk P; Lando PA; Shaw D; Stern PL; Dohlsten M
Br J Cancer; 2001 Jul; 85(1):129-36. PubMed ID: 11437414
[TBL] [Abstract][Full Text] [Related]
9. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
11. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
12. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity.
Hafner C; Wagner S; Allwardt D; Riemer AB; Scheiner O; Pehamberger H; Breiteneder H
Melanoma Res; 2005 Apr; 15(2):111-7. PubMed ID: 15846144
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
15. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
16. Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies.
Yang H; Chen ZJ; Kageshita T; Yamada M; Ferrone S
Eur J Immunol; 1993 Jul; 23(7):1671-7. PubMed ID: 7686858
[TBL] [Abstract][Full Text] [Related]
17. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
[TBL] [Abstract][Full Text] [Related]
18. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.
Wang X; Ko EC; Peng L; Gillies SD; Ferrone S
Cancer Res; 2005 Aug; 65(15):6976-83. PubMed ID: 16061683
[TBL] [Abstract][Full Text] [Related]
19. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
20. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
Forsberg G; Skartved NJ; Wallén-Ohman M; Nyhlén HC; Behm K; Hedlund G; Nederman T
J Immunother; 2010 Jun; 33(5):492-9. PubMed ID: 20463598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
